Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6013791 | 0.85 | KDM4E (0.46) | TBXAS1GAASMN1; SMN2FDPSTAAR1 | |
| SCHEMBL6013790 | 0.85 | TBXAS1 (0.44) | TBXAS1GAASMN1; SMN2FDPSTAAR1 | |
| Hydrochloric Acid SCHEMBL28900907 | 0.83 | KDM4E (0.49) | TBXAS1GAASMN1; SMN2FDPSTAAR1 | |
| Water SCHEMBL2827597 | 0.83 | TBXAS1 (0.42) | TBXAS1GAASMN1; SMN2FDPSTAAR1 | |
| SCHEMBL7866877 | 0.82 | HSD17B10 (0.50) | TBXAS1GAASMN1; SMN2TAAR1HTR1A | |
| SCHEMBL10716164 | 0.82 | TBXAS1 (0.41) | TBXAS1GAASMN1; SMN2FDPSTAAR1 | |
| SCHEMBL16540538 | 0.82 | GAA (0.43) | TBXAS1GAASMN1; SMN2FDPSTAAR1 | |
| SCHEMBL8519473 | 0.81 | TBXAS1 (0.50) | TBXAS1GAASMN1; SMN2FDPSTAAR1 | |
| SCHEMBL4151559 | 0.80 | FDPS (0.45) | TBXAS1GAASMN1; SMN2FDPSTAAR1 | |
| Hydrochloric Acid SCHEMBL7019349 | 0.80 | HSD17B10 (0.49) | TBXAS1GAASMN1; SMN2TAAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9803030-B2 | Modified saccharides | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-10-31 | — | — | US | disclosed |
| EP-2118145-B1 | MODIFIED SACCHARIDES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2548895-A1 | Modified saccharides | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| US-20100322958-A1 | MODIFIED SACCHARIDES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100322958-A1 | MODIFIED SACCHARIDES | MSR1, OXGR1, SUCNR1 | TBXAS1 2628/4885GAA 2121/4885SMN1; SMN2 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.